Literature DB >> 7999427

Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays.

E S Marshall1, J H Matthews, J H Shaw, J Nixon, P Tumewu, G J Finlay, K M Holdaway, B C Baguley.   

Abstract

Seven new low-passage melanoma lines were developed in this laboratory from clinical melanoma specimens and characterised for chromosome complement, DNA ploidy and S-phase content. The radiosensitivity of these lines was compared with that of eight established melanoma cell lines, FME, MM-96, SK-MEL-5, SK-MEL-28, SK-MEL-2, MALME-3M, M19-MEL and LOX-IMVI, using a 96-well microculture assay technique. Dose-response curves were determined using a 5-day incubation period and 6-h terminal [3H]thymidine-labelling period. Radiation (60Co source) was carried out under a lead wedge to provide a radiation dose range of 0-10 Gy, or by irradiating part of the plate (radiation dose 0 or 2 Gy). Data for a range of cell densities in a single 96-well plate were combined into a single regression equation incorporating linear quadratic terms for radiation dose and cell density. SF2 values were defined as the amount of thymidine incorporated following a radiation dose of 2 Gy, expressed as a fraction of that of unirradiated cells, and varied from 0.36 to 0.93. The reproducibility in repeat assays, as defined by the standard error of determinations at different passage numbers, was +/- 0.04. The newly developed lines exhibited a similar range of radiosensitivity to that of the established lines, and melanin content did not correlate with resistance. For nine of the lines, radiation parameters were also determined using a modified Courtenay clonogenic soft agar assay technique, and the results compared with the thymidine incorporation results, and a significant linear correlation was found between SF2 and SF2' (r = 0.89). The linear (alpha) and quadratic (beta) terms of the best-fit linear quadratic dose-response curves, were significantly correlated between the two assays. It is concluded for this series of human melanoma lines that proliferation assays in 96-well plates provide radiosensitivity parameters comparable to those using clonogenic assays.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7999427     DOI: 10.1016/0959-8049(94)90188-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  19 in total

1.  Analysis of radiation-induced changes to human melanoma cultures using a mathematical model.

Authors:  B Basse; W R Joseph; E S Marshall; B C Baguley
Journal:  Cell Prolif       Date:  2010-04       Impact factor: 6.831

2.  Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide.

Authors:  Catherine J Drummond; Graeme J Finlay; Laura Broome; Elaine S Marshall; Emma Richardson; Bruce C Baguley
Journal:  Invest New Drugs       Date:  2010-06-22       Impact factor: 3.850

Review 3.  Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.

Authors:  Kirtesh R Patel; David H Lawson; Ragini R Kudchadkar; Bradley C Carthon; Daniel E Oliver; Derick Okwan-Duodu; Rafi Ahmed; Mohammad K Khan
Journal:  Neuro Oncol       Date:  2015-05-25       Impact factor: 12.300

4.  A gene expression signature of invasive potential in metastatic melanoma cells.

Authors:  Aaron R Jeffs; Amy C Glover; Lynn J Slobbe; Li Wang; Shujie He; Jody A Hazlett; Anshul Awasthi; Adele G Woolley; Elaine S Marshall; Wayne R Joseph; Cristin G Print; Bruce C Baguley; Michael R Eccles
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

5.  Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.

Authors:  Ji Eun Kim; Clare Stones; Wayne R Joseph; Euphemia Leung; Graeme J Finlay; Andrew N Shelling; Wayne A Phillips; Peter R Shepherd; Bruce C Baguley
Journal:  BMC Cancer       Date:  2012-04-04       Impact factor: 4.430

6.  Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.

Authors:  Clare J Stones; Ji Eun Kim; Wayne R Joseph; Euphemia Leung; Elaine S Marshall; Graeme J Finlay; Andrew N Shelling; Bruce C Baguley
Journal:  Front Genet       Date:  2013-05-08       Impact factor: 4.599

7.  LASP1, a Newly Identified Melanocytic Protein with a Possible Role in Melanin Release, but Not in Melanoma Progression.

Authors:  Anjana Vaman V S; Heiko Poppe; Roland Houben; Thomas G P Grunewald; Matthias Goebeler; Elke Butt
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

8.  Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines.

Authors:  Ji Eun Kim; Euphemia Leung; Bruce C Baguley; Graeme J Finlay
Journal:  Front Genet       Date:  2013-05-31       Impact factor: 4.599

9.  The role of the hippo pathway in melanocytes and melanoma.

Authors:  Ji Eun Kim; Graeme J Finlay; Bruce C Baguley
Journal:  Front Oncol       Date:  2013-05-16       Impact factor: 6.244

10.  Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation.

Authors:  Aleksandra M Ristić-Fira; Lela B Korićanac; Jelena J Zakula; Lucia M Valastro; Gioacchin Iannolo; Giuseppe Privitera; Giacomo Cuttone; Ivan M Petrović
Journal:  J Exp Clin Cancer Res       Date:  2009-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.